A multinational randomized, controlled, clinical trial of etoricoxib inthetreatment of rheumatoid arthritis [ISRCTN25142273]

被引：84

作者：

Collantes E. ^{[1
]}

Curtis S.P. ^{[2
]}

Lee K.W. ^{[3
]}

Casas N. ^{[4
]}

McCarthy T. ^{[5
]}

Melian A. ^{[2
]}

Zhao P.L. ^{[2
]}

Rodgers D.B. ^{[2
]}

McCormick C.L. ^{[2
]}

Lee M. ^{[2
]}

Lines C.R. ^{[2
]}

Gertz B.J. ^{[2
]}

机构：

[1] Hospital Reina Sofia, Cordoba

[2] Merck and Co., Inc., Rahway, NJ

[3] Pamela Youde Nethersole E. Hospital, Hong Kong

[4] Clinica Reina Sofia, Bogata

[5] Manitoba Clinic, Winnipeg, Man.

来源：

BMC Family Practice | / 3卷 / 1期

关键词：

Rheumatoid Arthritis; Naproxen; Etoricoxib; Clinical Adverse Event; Patient Global Assessment;

D O I：

10.1186/1471-2296-3-10

中图分类号：

学科分类号：

摘要：

Background: Etoricoxib is a highly selective COX-2 inhibitor which was evaluated for the treatment of rheumatoid arthritis (RA). Methods: Double-blind, randomized, placebo and active comparator-controlled, 12-week study conducted at 67 sites in 28 countries. Eligible patients were chronic NSAID users who demonstrated a clinical worsening of arthritis upon withdrawal of prestudy NSAIDs. Patients received either placebo, etoricoxib 90 mg once daily, or naproxen 500 mg twice daily (2:2:1 allocation ratio). Primary efficacy measures included direct assessment of arthritis by counts of tender and swollen joints, and patient and investigator global assessments of disease activity. Key secondary measures included the Stanford Health Assessment Questionnaire, patient global assessment of pain, and the percentage of patients who achieved ACR20 responder criteria response (a composite of pain, inflammation, function, and global assessments). Tolerability was assessed by adverse events and routine laboratory evaluations. Results: 1171 patients were screened, 891 patients were randomized (N = 357 for placebo, N = 353 for etoricoxib, and N = 181 for naproxen), and 687 completed 12 weeks of treatment (N = 242 for placebo, N = 294 for etoricoxib, and N = 151 for naproxen). Compared with patients receiving placebo, patients receiving etoricoxib and naproxen showed significant improvements in all efficacy endpoints (p<0.05). Treatment responses were similar between the etoricoxib and naproxen groups for all endpoints. The percentage of patients who achieved ACR20 responder criteria response was 41% in the placebo group, 59% in the etoricoxib group, and 58% in the naproxen group. Etoricoxib and naproxen were both generally well tolerated. Conclusions: In this study, etoricoxib 90 mg once daily was more effective than placebo and similar in efficacy to naproxen 500 mg twice daily for treating patients with RA over 12 weeks. Etoricoxib 90 mg was generally well tolerated in RA patients.

引用

页码：1 / 10

页数：9

共 19 条

[1] Guidelines for monitoring drug therapy in rheumatoid arthritis, Arthritis Rheum, 39, pp. 723-731, (1996)
[2] Guidelines for the management of rheumatoid arthritis, Arthritis Rheum, 39, pp. 713-722, (1996)
[3] Wolfe M.M., Lichtenstein D.R., Singh G., Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs, N Engl J Med, 340, pp. 1888-1899, (1999)
[4] Fries J.F., Williams C.A., Bloch D.A., Michel B.A., Nonsteroidal anti-inflammatory drug-associated gastropathy: Incidence and risk factor models, Am J Med, 91, pp. 213-222, (1991)
[5] Van Riel P.L.C.M., Wijnands M.J.H., Van De Putte L.B.A., Evaluation and management of active inflammatory disease, Rheumatology, (1998)
[6] Bombardier C., Laine L., Reicin A., Et al., Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis, New Engl J Med, 343, pp. 1520-1528, (2000)
[7] Schnitzer T.J., Truitt K., Fleischmann R., Et al., The safety profile, tolerability, and effective dose range of rofecoxib in the treatment of rheumatoid arthritis, Clinical Therapeutics, 21, pp. 1688-1702, (1999)
[8] Emery P., Zeidler H., Kvien K.T., Et al., Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: Randomized double-blind comparison, Lancet, 354, pp. 2106-2111, (1999)
[9] Matsumoto A., Melian A., Mandel D.R., Et al., A randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis, J Rheumatology, (2002)
[10] Felson D.T., Anderson J.J., Boers M., Et al., American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis, Arthritis Rheum, 38, pp. 727-735, (1995)

← 1 2 →